Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis

Horng Chyuan Lin, Han Fang Cheng, Chun Hua Wang, Chien Ying Liu, Chih Teng Yu, Han Pin Kuo

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

To investigate whether aerosolized gentamicin (GM) prevents myeloperoxidase (MPO)-mediated airway injury and mucus hypersecretion, a short course of aerosol therapy (3 d) with GM 40 mg or 0.45% saline (saline) twice per day was conducted. Twenty-eight patients with bronchiectasis and mucus hypersecretion after adequate chest care and hydration were enrolled in a randomized, double-blind fashion. MPO levels in sputum collected on arising were determined by fluorometric assay at 655 nm before and after treatment. The sputum MPO level significantly decreased in patients receiving aerosolized GM, from 0.22 ± 0.04 to 0.14 ± 0.04 U/g (n = 15), but not in patients with saline inhalation (0.23 ± 0.03 to 0.17 ± 0.02 U/g; n = 11). The daily sputum amount significantly decreased from 94.6 ± 21.6 to 58.1 ± 17.8 ml (n = 13, p < 0.01) in the GM group, whereas it increased from 78.6 ± 25.4 ml to 120.5 ± 33.9 ml (n = 11, p < 0.05) in the saline group. The change in the amount of daily sputum was related to that in the sputum MPO level in the GM group (r = 0.61; p < 0.01), inhalation of GM, but not saline, significantly (p < 0.05) increased the value of peak expiratory flow (PEF) from 186.4 ± 25.1 to 216.4 ± 26.4 L/min and decreased the variability of PEF from 24.6 ± 5,1 to 6,1 ± 2.3%. The nocturnal desaturation and the 6- min walking distances were also significantly improved in the GM group (11.2 ± 3.8 to 0.6 ± 0.5 min/h; 324.9 ± 43.1 to 408.1 ± 25.9 m; p < 0.05; respectively), but not in the saline group. Subjective improvements in the Borg scale and self-sputum assessment were found in the GM group only. In conclusion, aerosolized GM is effective in improving airway hypersecretion and inflammation in patients with bronchiectasis.

Original languageEnglish
Pages (from-to)2024-2029
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume155
Issue number6
DOIs
Publication statusPublished - Jan 1 1997
Externally publishedYes

Fingerprint

Bronchiectasis
Mucus
Gentamicins
Neutrophils
Sputum
Peroxidase
Inhalation
Aerosols
Walking
Thorax
Inflammation
Wounds and Injuries

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. / Lin, Horng Chyuan; Cheng, Han Fang; Wang, Chun Hua; Liu, Chien Ying; Yu, Chih Teng; Kuo, Han Pin.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 155, No. 6, 01.01.1997, p. 2024-2029.

Research output: Contribution to journalArticle

Lin, Horng Chyuan ; Cheng, Han Fang ; Wang, Chun Hua ; Liu, Chien Ying ; Yu, Chih Teng ; Kuo, Han Pin. / Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. In: American Journal of Respiratory and Critical Care Medicine. 1997 ; Vol. 155, No. 6. pp. 2024-2029.
@article{06e0c0f4ce0f405585f94a4599dc32b8,
title = "Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis",
abstract = "To investigate whether aerosolized gentamicin (GM) prevents myeloperoxidase (MPO)-mediated airway injury and mucus hypersecretion, a short course of aerosol therapy (3 d) with GM 40 mg or 0.45{\%} saline (saline) twice per day was conducted. Twenty-eight patients with bronchiectasis and mucus hypersecretion after adequate chest care and hydration were enrolled in a randomized, double-blind fashion. MPO levels in sputum collected on arising were determined by fluorometric assay at 655 nm before and after treatment. The sputum MPO level significantly decreased in patients receiving aerosolized GM, from 0.22 ± 0.04 to 0.14 ± 0.04 U/g (n = 15), but not in patients with saline inhalation (0.23 ± 0.03 to 0.17 ± 0.02 U/g; n = 11). The daily sputum amount significantly decreased from 94.6 ± 21.6 to 58.1 ± 17.8 ml (n = 13, p < 0.01) in the GM group, whereas it increased from 78.6 ± 25.4 ml to 120.5 ± 33.9 ml (n = 11, p < 0.05) in the saline group. The change in the amount of daily sputum was related to that in the sputum MPO level in the GM group (r = 0.61; p < 0.01), inhalation of GM, but not saline, significantly (p < 0.05) increased the value of peak expiratory flow (PEF) from 186.4 ± 25.1 to 216.4 ± 26.4 L/min and decreased the variability of PEF from 24.6 ± 5,1 to 6,1 ± 2.3{\%}. The nocturnal desaturation and the 6- min walking distances were also significantly improved in the GM group (11.2 ± 3.8 to 0.6 ± 0.5 min/h; 324.9 ± 43.1 to 408.1 ± 25.9 m; p < 0.05; respectively), but not in the saline group. Subjective improvements in the Borg scale and self-sputum assessment were found in the GM group only. In conclusion, aerosolized GM is effective in improving airway hypersecretion and inflammation in patients with bronchiectasis.",
author = "Lin, {Horng Chyuan} and Cheng, {Han Fang} and Wang, {Chun Hua} and Liu, {Chien Ying} and Yu, {Chih Teng} and Kuo, {Han Pin}",
year = "1997",
month = "1",
day = "1",
doi = "10.1164/ajrccm.155.6.9196111",
language = "English",
volume = "155",
pages = "2024--2029",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis

AU - Lin, Horng Chyuan

AU - Cheng, Han Fang

AU - Wang, Chun Hua

AU - Liu, Chien Ying

AU - Yu, Chih Teng

AU - Kuo, Han Pin

PY - 1997/1/1

Y1 - 1997/1/1

N2 - To investigate whether aerosolized gentamicin (GM) prevents myeloperoxidase (MPO)-mediated airway injury and mucus hypersecretion, a short course of aerosol therapy (3 d) with GM 40 mg or 0.45% saline (saline) twice per day was conducted. Twenty-eight patients with bronchiectasis and mucus hypersecretion after adequate chest care and hydration were enrolled in a randomized, double-blind fashion. MPO levels in sputum collected on arising were determined by fluorometric assay at 655 nm before and after treatment. The sputum MPO level significantly decreased in patients receiving aerosolized GM, from 0.22 ± 0.04 to 0.14 ± 0.04 U/g (n = 15), but not in patients with saline inhalation (0.23 ± 0.03 to 0.17 ± 0.02 U/g; n = 11). The daily sputum amount significantly decreased from 94.6 ± 21.6 to 58.1 ± 17.8 ml (n = 13, p < 0.01) in the GM group, whereas it increased from 78.6 ± 25.4 ml to 120.5 ± 33.9 ml (n = 11, p < 0.05) in the saline group. The change in the amount of daily sputum was related to that in the sputum MPO level in the GM group (r = 0.61; p < 0.01), inhalation of GM, but not saline, significantly (p < 0.05) increased the value of peak expiratory flow (PEF) from 186.4 ± 25.1 to 216.4 ± 26.4 L/min and decreased the variability of PEF from 24.6 ± 5,1 to 6,1 ± 2.3%. The nocturnal desaturation and the 6- min walking distances were also significantly improved in the GM group (11.2 ± 3.8 to 0.6 ± 0.5 min/h; 324.9 ± 43.1 to 408.1 ± 25.9 m; p < 0.05; respectively), but not in the saline group. Subjective improvements in the Borg scale and self-sputum assessment were found in the GM group only. In conclusion, aerosolized GM is effective in improving airway hypersecretion and inflammation in patients with bronchiectasis.

AB - To investigate whether aerosolized gentamicin (GM) prevents myeloperoxidase (MPO)-mediated airway injury and mucus hypersecretion, a short course of aerosol therapy (3 d) with GM 40 mg or 0.45% saline (saline) twice per day was conducted. Twenty-eight patients with bronchiectasis and mucus hypersecretion after adequate chest care and hydration were enrolled in a randomized, double-blind fashion. MPO levels in sputum collected on arising were determined by fluorometric assay at 655 nm before and after treatment. The sputum MPO level significantly decreased in patients receiving aerosolized GM, from 0.22 ± 0.04 to 0.14 ± 0.04 U/g (n = 15), but not in patients with saline inhalation (0.23 ± 0.03 to 0.17 ± 0.02 U/g; n = 11). The daily sputum amount significantly decreased from 94.6 ± 21.6 to 58.1 ± 17.8 ml (n = 13, p < 0.01) in the GM group, whereas it increased from 78.6 ± 25.4 ml to 120.5 ± 33.9 ml (n = 11, p < 0.05) in the saline group. The change in the amount of daily sputum was related to that in the sputum MPO level in the GM group (r = 0.61; p < 0.01), inhalation of GM, but not saline, significantly (p < 0.05) increased the value of peak expiratory flow (PEF) from 186.4 ± 25.1 to 216.4 ± 26.4 L/min and decreased the variability of PEF from 24.6 ± 5,1 to 6,1 ± 2.3%. The nocturnal desaturation and the 6- min walking distances were also significantly improved in the GM group (11.2 ± 3.8 to 0.6 ± 0.5 min/h; 324.9 ± 43.1 to 408.1 ± 25.9 m; p < 0.05; respectively), but not in the saline group. Subjective improvements in the Borg scale and self-sputum assessment were found in the GM group only. In conclusion, aerosolized GM is effective in improving airway hypersecretion and inflammation in patients with bronchiectasis.

UR - http://www.scopus.com/inward/record.url?scp=0030977508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030977508&partnerID=8YFLogxK

U2 - 10.1164/ajrccm.155.6.9196111

DO - 10.1164/ajrccm.155.6.9196111

M3 - Article

C2 - 9196111

AN - SCOPUS:0030977508

VL - 155

SP - 2024

EP - 2029

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -